Multiple sclerosis and COVID-19
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
32686774
DOI
10.5507/bp.2020.033
Knihovny.cz E-zdroje
- Klíčová slova
- COVID-19, coronavirus, immunomodulatory therapy, multiple sclerosis,
- MeSH
- asymptomatické nemoci epidemiologie MeSH
- autoimunita MeSH
- Betacoronavirus fyziologie MeSH
- COVID-19 MeSH
- imunologické faktory farmakologie MeSH
- imunomodulace imunologie MeSH
- koronavirové infekce * epidemiologie imunologie terapie virologie MeSH
- lidé MeSH
- pandemie * MeSH
- roztroušená skleróza * epidemiologie imunologie terapie MeSH
- SARS-CoV-2 MeSH
- virová pneumonie * epidemiologie imunologie terapie virologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- imunologické faktory MeSH
This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).
Citace poskytuje Crossref.org
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia
